From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Current legislation before Congress, including the Modernizing and Ensuring PBM Accountability Act (S.2973) and the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 (S.3430), ...

The review of Minnesota-based Optum’s business practices by the Mississippi Board of Pharmacy indicated that the company paid independent pharmacies in Mississippi rates lower than chains and ...

Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

As Cigna and Humana pick back up on the potential for a megamerger, executives will be keeping a close eye on the outcomes of ...

The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

Former President Donald Trump's reascension to the Oval Office puts Affordable Care Act rules and subsidies in doubt, and raises many questions for the healthcare sector.

The usual PBM strategy cuts an independent pharmacy's share of the prescription revenue to just 3 cents per pill dispensed, ...

The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...

By Andy Miller, KFF Health News. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities have drawn scrutiny from Congress, the Federal Trade Commission, and ...

Despite reports this fall that the two payers had reopened merger talks, Cigna plans to use excess cash to buy back its ...

The Cigna Group reported $739 million in profit for the third quarter, a figure that accounts for a $1 billion after-tax ...